HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Short-term stability of a new generic sodium ferric gluconate in complex with sucrose.

AbstractBACKGROUND:
Sodium ferric gluconate in complex (SFG) is used to treat iron deficiency anemia in patients aged ≥6 years undergoing chronic hemodialysis and receiving supplemental epoetin therapy. Both the branded product (Ferrlecit, branded SFG) and a new generic version of sodium ferric gluconate in complex (Nulecit; generic SFG) are provided in 5 mL vials. SFG may be administered by slow intravenous (IV) injection of the undiluted product or by 1 h IV infusion after dilution in 100 mL 0.9% sodium chloride. This study evaluated the short-term stability of undiluted and diluted generic SFG at room temperature and under refrigeration.
METHODS:
Samples of generic SFG undiluted in 10 mL syringes or diluted in IV infusion bags containing 0.9% sodium chloride solution were stored at room temperature or under refrigerated conditions (2-8°C). Samples at room temperature were stored for ≤48 h if undiluted and for ≤24 h if diluted. All refrigerated samples were stored for ≤7 days. Parameters evaluated were elemental iron (Fe) concentration and SFG apparent molecular weight. All tests were performed on two lots of the generic product.
RESULTS:
Fe concentrations were identical in both lots and did not vary substantially over time under different conditions of storage or dilution. SFG apparent molecular weight varied across all samples from 306,000 to 354,000 Daltons, well within the range of 289,000 to 440,000 Daltons specified as the molecular weight in the FDA-approved prescribing information.
CONCLUSION:
Iron content and SFG apparent molecular weight were stable under all experimental conditions. Undiluted generic SFG was stable for ≥2 days at room temperature and ≥7 days under refrigerated conditions, and generic SFG diluted in IV infusion bags containing 0.9% sodium chloride solution was stable for ≥1 day at room temperature and ≥7 days under refrigerated conditions.
AuthorsDavid Baribeault
JournalCurrent medical research and opinion (Curr Med Res Opin) Vol. 27 Issue 12 Pg. 2241-3 (Dec 2011) ISSN: 1473-4877 [Electronic] England
PMID21992082 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Drugs, Generic
  • Ferric Compounds
  • Hematinics
  • Sweetening Agents
  • Sucrose
  • ferric gluconate
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia (drug therapy)
  • Child
  • Drug Stability
  • Drugs, Generic (analysis, chemistry, therapeutic use)
  • Female
  • Ferric Compounds (analysis, chemistry, therapeutic use)
  • Hematinics (analysis, chemistry, therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Sucrose (analysis, chemistry, therapeutic use)
  • Sweetening Agents (analysis, chemistry, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: